The development of anti‐PD‐(L)1 agents has revolutionized the treatment paradigms of non‐small cell lung cancer (NSCLC) with long lasting therapy responses and clinically meaningful overall survival benefit.4, 5, 6, 7, 8, 15. This evidence concerns the gene CD274 and non-small cell lung carcinoma.